Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

821. Nicotine for schizophrenia. (Abstract)

Nicotine for schizophrenia. The proportion of people with schizophrenia who smoke is very high, and as a rule, they tend to be heavier smokers when compared to the general population and those with other psychiatric disorders. Nicotine, the psychoactive component in tobacco, is thought to produce psychological effects that help to alleviate psychotic symptoms.To examine the effects of nicotine and related products in the treatment of schizophrenia.We electronically searched the Cochrane (...) Schizophrenia Group's Register (April 2005), supplemented with manually inspecting references of all identified studies and by contacting authors of studies where required.We included all randomised clinical trials comparing nicotine or related products as a sole or adjunctive treatment for people with schizophrenia or other similar serious, non-affective psychotic illness.Citations and, where possible, abstracts were independently inspected by reviewers and the papers ordered were scrutinised and quality

2006 Cochrane

822. Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain

Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain Gutierrez-Recacha P, Chisholm D, Haro J M, Salvador-Carulla L, Ayuso-Mateos J L Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study aimed to compare different clinical interventions for the treatment of schizophrenia at the population level. In particular: older antipsychotic drugs alone (haloperidol); new antipsychotic drugs alone (risperidone); older antipsychotic drugs in combination

2006 NHS Economic Evaluation Database.

823. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)

Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

824. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis

Antipsychotics in early onset schizophrenia: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

825. Group cognitive behavioural therapy for schizophrenia: a systematic review of the literature

Group cognitive behavioural therapy for schizophrenia: a systematic review of the literature Group cognitive behavioural therapy for schizophrenia: a systematic review of the literature Group cognitive behavioural therapy for schizophrenia: a systematic review of the literature Lawrence R, Bradshaw T, Mairs H CRD summary The review concluded that, although positive results have been reported for cognitive-behavioural group therapy, these are not consistent between studies and the methodological (...) weaknesses of the studies compromise the results. The authors appropriately considered the methodological weaknesses and differences across the studies, and their cautious conclusions appear appropriate based on the evidence presented. Authors' objectives To evaluate the effectiveness of cognitive-behavioural group therapy (CBGT) for the treatment of schizophrenia. Searching MEDLINE, PsycINFO, CINAHL, EMBASE, the Cochrane Library, National Research Register and SIGLE were searched from 1993 for studies

2006 DARE.

826. Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis

Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis Painuly N, Chakrabarti S CRD summary The review examined whether the combination of electroconvulsive therapy (...) (ECT) and antipsychotic drugs was more efficacious than antipsychotic drugs alone in the acute phase treatment of schizophrenia. The authors concluded that ECT-antipsychotic combinations might be better than antipsychotic drugs alone in the first few weeks of treatment. The authors' conclusions were suitably cautious and are likely to be reliable. Authors' objectives To examine whether the combination of electroconvulsive therapy (ECT) and antipsychotic drugs was more efficacious than antipsychotic

2006 DARE.

827. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment Randomised controlled trials of conventional antipsychotic (...) versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment Lewis S W, Davies L, Jones P B, Barnes T R E, Murray R M, Kerwin R, Taylor D, Hayhurst K P, Markwick A, Lloyd H, Dunn G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lewis S W, Davies

2006 Health Technology Assessment (HTA) Database.

828. Cost-effectiveness analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study in Spain

Cost-effectiveness analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study in Spain Cost-effectiveness analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study in Spain Cost-effectiveness analysis of schizophrenia relapse prevention: an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study in Spain Bernardo M, Azanza J R (...) , Rubio-Terres C, Rejas J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the atypical antipsychotic ziprasidone (ZIP), in differing doses, for the treatment of schizophrenia. Type of intervention Treatment

2006 NHS Economic Evaluation Database.

829. A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany

A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany Beard A M, Maciver F, Clouth J, Ruther E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of olanzapine with risperidone in the treatment of patients with an established history of schizophrenia. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients currently

2006 NHS Economic Evaluation Database.

830. Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish 'Parachute Project' and two comparison groups

Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish 'Parachute Project' and two comparison groups Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish 'Parachute Project' and two comparison groups Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish 'Parachute Project' and two comparison groups Cullberg J, Mattsson M (...) schizophrenia syndrome. The programme was delivered by a first episode psychotic (FEP) patient team within 24 hours after the first contact with the psychiatric clinic (in the hospital or patient's home). The intervention attempted to involve the family, or those closest to the patient, in the future delivery of health care. According to the project, antipsychotic medication should not be considered as the first choice of treatment during the initial weeks of treatment, but benzodiazepines and similar

2006 NHS Economic Evaluation Database.

831. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. Full Text available with Trip Pro

Clozapine alone versus clozapine and risperidone with refractory schizophrenia. The treatment of schizophrenia with multiple antipsychotic drugs is common, but the benefits and risks are not known.In a randomized, double-blind study, we evaluated patients with schizophrenia and a poor response to treatment with clozapine. The patients continued to take clozapine and were randomly assigned to receive eight weeks of daily augmentation with 3 mg of risperidone or with placebo. This course (...) schizophrenia. (ClinicalTrials.gov number, NCT00272584).Copyright 2006 Massachusetts Medical Society.

2006 NEJM Controlled trial quality: predicted high

832. Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Full Text available with Trip Pro

Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Article Text Therapeutics

2006 Evidence-Based Mental Health

833. Review: high doses of antipsychotic drugs are no more or less effective than medium doses in people with schizophrenia Full Text available with Trip Pro

Review: high doses of antipsychotic drugs are no more or less effective than medium doses in people with schizophrenia Review: high doses of antipsychotic drugs are no more or less effective than medium doses in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: high doses of antipsychotic drugs are no more or less effective than medium doses in people with schizophrenia Article Text Therapeutics Review

2005 Evidence-Based Mental Health

834. Cognitive behavioural therapy improves psychotic symptoms at 18 months in people with schizophrenia Full Text available with Trip Pro

Cognitive behavioural therapy improves psychotic symptoms at 18 months in people with schizophrenia Cognitive behavioural therapy improves psychotic symptoms at 18 months in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cognitive behavioural therapy improves psychotic symptoms at 18 months in people with schizophrenia Article Text Therapeutics Cognitive behavioural therapy improves psychotic symptoms at 18

2005 Evidence-Based Mental Health

835. Review: in people with schizophrenia, lithium is ineffective as sole therapy, while evidence on augmenting antipsychotics with lithium is inconclusive Full Text available with Trip Pro

Review: in people with schizophrenia, lithium is ineffective as sole therapy, while evidence on augmenting antipsychotics with lithium is inconclusive Review: in people with schizophrenia, lithium is ineffective as sole therapy, while evidence on augmenting antipsychotics with lithium is inconclusive | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: in people with schizophrenia, lithium is ineffective as sole therapy, while

2005 Evidence-Based Mental Health

836. Art therapy for schizophrenia or schizophrenia-like illnesses. Full Text available with Trip Pro

Art therapy for schizophrenia or schizophrenia-like illnesses. Many people with schizophrenia or schizophrenia-like illnesses continue to experience symptoms in spite of medication. In addition to medication, creative therapies, such as art therapy, may be helpful. Art therapy allows exploration of the patient's inner world in a non-threatening way through a therapeutic relationship and the use of art materials. It was mainly developed in adult psychiatric inpatient units and was designed (...) for use with people for whom verbal psychotherapy would be impossible.To review the effects of art therapy as an adjunctive treatment for schizophrenia compared with standard care and other psychosocial interventions.We updated the search of the Cochrane Schizophrenia Group's Register (February 2005), hand searched reference lists and 'Inscape' (the Journal of the British Association of Art Therapists), and contacted relevant authors.We included all randomised controlled trials that compared art

2005 Cochrane

837. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. Full Text available with Trip Pro

Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. Schizophrenia is a common major mental disorder. Intrauterine nutritional deficiency may increase the risk of schizophrenia. The main evidence comes from studies of the 1944-1945 Dutch Hunger Winter when a sharp and time-limited decline in food intake occurred. The most exposed cohort conceived during the famine showed a 2-fold increased risk of schizophrenia.To determine whether those who endured (...) a massive 1959-1961 famine in China experienced similar results.The risk of schizophrenia was examined in the Wuhu region of Anhui, one of the most affected provinces. Rates were compared among those born before, during, and after the famine years. Wuhu and its surrounding 6 counties are served by a single psychiatric hospital. All psychiatric case records for the years 1971 through 2001 were examined, and clinical and sociodemographic information on patients with schizophrenia was extracted

2005 JAMA

838. Multiple family group treatment reduces distress for caregivers of people with schizophrenia Full Text available with Trip Pro

Multiple family group treatment reduces distress for caregivers of people with schizophrenia Multiple family group treatment reduces distress for caregivers of people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Multiple family group treatment reduces distress for caregivers of people with schizophrenia Article Text Therapeutics Multiple family group treatment reduces distress for caregivers of people

2005 Evidence-Based Mental Health

839. Risperidone improves severe tardive dyskinesia in people with schizophrenia Full Text available with Trip Pro

Risperidone improves severe tardive dyskinesia in people with schizophrenia Risperidone improves severe tardive dyskinesia in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone improves severe tardive dyskinesia in people with schizophrenia Article Text Therapeutics Risperidone improves severe tardive dyskinesia in people with schizophrenia Free Rajiv Tandon , MD Statistics from Altmetric.com Bai Y

2005 Evidence-Based Mental Health

840. Depot perphenazine decanoate and enanthate for schizophrenia. (Abstract)

Depot perphenazine decanoate and enanthate for schizophrenia. Antipsychotic drugs are usually given orally but compliance with medication given by this route may be difficult to quantify. The development of depot injections in the 1960s gave rise to extensive use of depots as a means of long-term maintenance treatment. Perphenazine decanoate and enanthate are depot antipsychotics that belong to the phenothiazine family and have a piperazine ethanol side chain.To assess the effects of depot (...) perphenazine decanoate and enanthate versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes.We updated previous searches of the Cochrane Schizophrenia Group Register (June 1998), Biological Abstracts (1982-1998), the Cochrane Library (Issue 2, 1998), EMBASE (1980-1998), MEDLINE (1966-1998), and PsycLIT (1974-1998) by searching the Cochrane Schizophrenia Group Register (March 2004). References of all

2005 Cochrane